<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD01650000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P06213</UniProt_ID>
  <Seq_Length>1382</Seq_Length>
  <Molecule_Weight>156319</Molecule_Weight>
  <KEGG_ID>hsa:3643</KEGG_ID>
  <Orthology_ID>K04527</Orthology_ID>
  <Function_Summary>Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF00041:fn3@@PF00757:Furin-like@@PF07714:Pkinase_Tyr@@PF01030:Recep_L_domain</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>IR</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a phosphatidylinositol 3-kinase, any enzyme that catalyzes the addition of a phosphate group to an inositol lipid at the 3' position of the inositol ring.</Detail>
      <Keyword>Phosphatidylinositol 3-kinase binding</Keyword>
      <Ontology_ID>GO:0043548</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a phosphotyrosine-binding (PTB) domain of a protein.</Detail>
      <Keyword>PTB domain binding</Keyword>
      <Ontology_ID>GO:0051425</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a SH2 domain (Src homology 2) of a protein, a protein domain of about 100 amino-acid residues and belonging to the alpha + beta domain class.</Detail>
      <Keyword>SH2 domain binding</Keyword>
      <Ontology_ID>GO:0042169</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + receptor signalling protein tyrosine = ADP + receptor signalling protein phosphate.</Detail>
      <Keyword>Receptor signaling protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004716</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with insulin-like growth factor I.</Detail>
      <Keyword>Insulin-like growth factor I binding</Keyword>
      <Ontology_ID>GO:0031994</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with insulin to initiate a change in cell activity.</Detail>
      <Keyword>Insulin receptor activity</Keyword>
      <Ontology_ID>GO:0005009</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with insulin-like growth factor II.</Detail>
      <Keyword>Insulin-like growth factor II binding</Keyword>
      <Ontology_ID>GO:0031995</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with GTP, guanosine triphosphate.</Detail>
      <Keyword>GTP binding</Keyword>
      <Ontology_ID>GO:0005525</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with insulin, a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.</Detail>
      <Keyword>Insulin binding</Keyword>
      <Ontology_ID>GO:0043559</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the insulin-like growth factor receptor.</Detail>
      <Keyword>Insulin-like growth factor receptor binding</Keyword>
      <Ontology_ID>GO:0005159</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any of the insulin receptor substrate (IRS) proteins, adaptor proteins that bind to the transphosphorylated insulin and insulin-like growth factor receptors, are themselves phosphorylated and in turn recruit SH2 domain-containing signaling molecules to form a productive signaling complex.</Detail>
      <Keyword>Insulin receptor substrate binding</Keyword>
      <Ontology_ID>GO:0043560</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>1282</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>1075</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>1206</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>1012</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>146</Position>
      <Original>Ile</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>858</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>1020</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>1227</Position>
      <Original>Trp</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>925</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>439</Position>
      <Original>Trp</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>458</Position>
      <Original>Asn</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>119</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>1065</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>1205</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>279</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>42</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>280</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>393</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>1162</Position>
      <Original>Ala</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>301</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>55</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>120</Position>
      <Original>Leu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>350</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>228</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>1095</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>86</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>2</Position>
      <Original>Ala</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>279</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>695</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>811</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1143</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>1035</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>487</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>89</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>1378</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>937</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>1201</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>409</Position>
      <Original>Phe</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>1023</Position>
      <Original>Ile</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>492</Position>
      <Original>Gln</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>926</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>448</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>113</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>58</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>997</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>762</Position>
      <Original>Arg</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>167</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>1158</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>1158</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>1161</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>1361</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>1201</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>1055</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>236</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>1206</Position>
      <Original>Glu</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>830</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>386</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>171</Position>
      <Original>Tyr</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>1191</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>220</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>1119</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>260</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>1220</Position>
      <Original>Trp</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>489</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1180</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade.</Detail>
      <Keyword>Positive regulation of MAPKKK cascade</Keyword>
      <Ontology_ID>GO:0043410</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that initiates the activity of the inactive enzyme protein kinase B.</Detail>
      <Keyword>Activation of protein kinase B activity</Keyword>
      <Ontology_ID>GO:0032148</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of cellular DNA-dependent transcription.</Detail>
      <Keyword>Regulation of transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0006355</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.</Detail>
      <Keyword>G-protein coupled receptor protein signaling pathway</Keyword>
      <Ontology_ID>GO:0007186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.</Detail>
      <Keyword>Positive regulation of respiratory burst</Keyword>
      <Ontology_ID>GO:0060267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The developmental process in which the heart is generated and organized. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.</Detail>
      <Keyword>Heart morphogenesis</Keyword>
      <Ontology_ID>GO:0003007</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.</Detail>
      <Keyword>Protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0046777</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of DNA replication.</Detail>
      <Keyword>Positive regulation of DNA replication</Keyword>
      <Ontology_ID>GO:0045740</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the import of the hexose monosaccharide glucose into a cell or organelle.</Detail>
      <Keyword>Positive regulation of glucose import</Keyword>
      <Ontology_ID>GO:0046326</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The formation of a protein heterotetramer, a macromolecular structure consisting of four noncovalently associated subunits, of which not all are identical.</Detail>
      <Keyword>Protein heterotetramerization</Keyword>
      <Ontology_ID>GO:0051290</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.</Detail>
      <Keyword>Positive regulation of nitric oxide biosynthetic process</Keyword>
      <Ontology_ID>GO:0045429</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen.</Detail>
      <Keyword>Positive regulation of glycogen biosynthetic process</Keyword>
      <Ontology_ID>GO:0045725</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any virus-induced change in the morphological, biochemical, or growth parameters of a cell.</Detail>
      <Keyword>Transformation of host cell by virus</Keyword>
      <Ontology_ID>GO:0019087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. Includes the formation of carbohydrate derivatives by the addition of a carbohydrate residue to another molecule.</Detail>
      <Keyword>Carbohydrate metabolic process</Keyword>
      <Ontology_ID>GO:0005975</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of mitosis.</Detail>
      <Keyword>Positive regulation of mitosis</Keyword>
      <Ontology_ID>GO:0045840</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of glycolysis.</Detail>
      <Keyword>Positive regulation of glycolysis</Keyword>
      <Ontology_ID>GO:0045821</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the protein kinase B signaling cascade, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.</Detail>
      <Keyword>Positive regulation of protein kinase B signaling cascade</Keyword>
      <Ontology_ID>GO:0051897</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of glucose within an organism or cell.</Detail>
      <Keyword>Glucose homeostasis</Keyword>
      <Ontology_ID>GO:0042593</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine.</Detail>
      <Keyword>Peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0018108</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell migration.</Detail>
      <Keyword>Positive regulation of cell migration</Keyword>
      <Ontology_ID>GO:0030335</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates, maintains or increases the rate of developmental growth.</Detail>
      <Keyword>Positive regulation of developmental growth</Keyword>
      <Ontology_ID>GO:0048639</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The initiation of the activity of the inactive enzyme MAP kinase by phosphorylation by a MAPKK.</Detail>
      <Keyword>Activation of MAPK activity</Keyword>
      <Ontology_ID>GO:0000187</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of embryonic development.</Detail>
      <Keyword>Regulation of embryonic development</Keyword>
      <Ontology_ID>GO:0045995</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.</Detail>
      <Keyword>Positive regulation of protein phosphorylation</Keyword>
      <Ontology_ID>GO:0001934</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>407</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1348</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1354</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1361</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>401</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1189</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1190</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1064</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>999</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1011</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1112</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1185</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>992</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>400</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1379</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1355</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHLQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYALVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNEECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECLGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQGCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGCTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETLEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQERNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFSDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWERQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQILKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAFPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYVSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCVSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEMEFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSNPS</Protein_Seq>
    <DNA_Seq>GGGGGGCTGCGCGGCCGGGTCGGTGCGCACACGAGAAGGACGCGCGGCCCCCAGCGCTCTTGGGGGCCGCCTCGGAGCATGACCCCCGCGGGCCAGCGCCGCGCGCCTGATCCGAGGAGACCCCGCGCTCCCGCAGCCATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAGGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTGGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACCCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGGTCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAGGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTCATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCGACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTGGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTGGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGTGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGCTGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACGATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCACCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGCACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAGCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCCTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTGGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGACTGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAACTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAGAGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTTAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGGCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAGAATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGACATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATGCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCGGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACCAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTGAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAGAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTGCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGTGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTGAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTTTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAACGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTCCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAGGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATCGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTCAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAAATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTGATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTCTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAACTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACCTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGCCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGAAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTCAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGAGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGCAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAACGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGCTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTGGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCAGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCGGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTGGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATGACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTACGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGGTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTGTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAACTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGGCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAGGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAGTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCGGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCTTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAATCCTTCCTAACAGTGCCTACCGTGGCGGGGGCGGGCAGGGGTTCCCATTTTCGCTTTCCTCTGGTTTGAAAGCCTCTGGAAAACTCAGGATTCTCACGACTCTACCATGTCCAGTGGAGTTCAGAGATCGTTCCTATACATTTCTGTTCATCTTAAGGTGGACTCGTTTGGTTACCAATTTAACTAGTCCTGCAGAGGATTTAACTGTGAACCTGGAGGGCAAGGGGTTTCCACAGTTGCTGCTCCTTTGGGGCAACGACGGTTTCAAACCAGGATTTTGTGTTTTTTCGTTCCCCCCACCCGCCCCCAGCAGATGGAAAGAAAGCACCTGTTTTTACAAATTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCTGGTGTCTGAGCTTCAGTATAAAAGACAAAACTTCCTGTTTGTGGAACAAAATTTCGAAAGAAAAAACCAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Peripheral nerve</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skin</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Striated muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lymphoblasts</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Spleen</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Fibroblasts</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane Associated</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>INSR</Gene_Name>
    <Gene_ID>3643</Gene_ID>
    <Genbank_ACCN>NM_000208</Genbank_ACCN>
    <Protein_ACCN>NP_000199</Protein_ACCN>
    <HGNC_ID>6091</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3643</Gene_URL>
    <UCSC_ID>uc002mge.1</UCSC_ID>
    <EMBL_ID>ENSG00000171105</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_insulin_resistant_with_acanthosis_nigricans?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Noninsulin-Dependent, Association with</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_noninsulin_dependent_association_with?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Resistance</Disease_Name>
      <Disease_Detail>Insulin Resistance</Disease_Detail>
      <Disease_DB>INS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_resistance?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Autoimmune Syndrome</Disease_Name>
      <Disease_Detail>Insulin Autoimmune Syndrome</Disease_Detail>
      <Disease_DB>INS006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_autoimmune_syndrome?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fetal Macrosomia</Disease_Name>
      <Disease_Detail>Fetal Macrosomia</Disease_Detail>
      <Disease_DB>FTL021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fetal_macrosomia?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myotonic Dystrophy</Disease_Name>
      <Disease_Detail>Myotonic Dystrophy</Disease_Detail>
      <Disease_DB>MYT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myotonic_dystrophy?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acanthosis Nigricans</Disease_Name>
      <Disease_Detail>Acanthosis Nigricans</Disease_Detail>
      <Disease_DB>ACN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acanthosis_nigricans?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Donohue Syndrome</Disease_Name>
      <Disease_Detail>Donohue Syndrome</Disease_Detail>
      <Disease_DB>DNH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/donohue_syndrome?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemihypertrophy</Disease_Name>
      <Disease_Detail>Hemihypertrophy</Disease_Detail>
      <Disease_DB>HMH002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemihypertrophy?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2 Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TYP009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2_diabetes_mellitus?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rabson-Mendenhall Syndrome</Disease_Name>
      <Disease_Detail>Rabson-Mendenhall Syndrome</Disease_Detail>
      <Disease_DB>RBS003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rabson_mendenhall_syndrome?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperinsulinemic Hypoglycemia, Familial, 5</Disease_Name>
      <Disease_Detail>Hyperinsulinemic Hypoglycemia</Disease_Detail>
      <Disease_DB>HYP326</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperinsulinemic_hypoglycemia_familial_5?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Noninsulin-Dependent, 2</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_noninsulin_dependent_2?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Berardinelli-Seip Congenital Lipodystrophy</Disease_Name>
      <Disease_Detail>Berardinelli-Seip Congenital Lipodystrophy</Disease_Detail>
      <Disease_DB>BRR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/berardinelli_seip_congenital_lipodystrophy?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acanthocytosis</Disease_Name>
      <Disease_Detail>Acanthocytosis</Disease_Detail>
      <Disease_DB>ACN014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acanthocytosis?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fasting Hypoglycemia</Disease_Name>
      <Disease_Detail>Fasting Hypoglycemia</Disease_Detail>
      <Disease_DB>FST010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fasting_hypoglycemia?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alzheimer's Disease</Disease_Name>
      <Disease_Detail>Alzheimer's Disease</Disease_Detail>
      <Disease_DB>ALZ001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alzheimers_disease?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myotonic Dystrophy Type 2</Disease_Name>
      <Disease_Detail>Myotonic Dystrophy</Disease_Detail>
      <Disease_DB>MYT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myotonic_dystrophy_type_2?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Noninsulin-Dependent</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_noninsulin_dependent?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperinsulinemic Hypoglycemia</Disease_Name>
      <Disease_Detail>Hyperinsulinemic Hypoglycemia</Disease_Detail>
      <Disease_DB>HYP050</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperinsulinemic_hypoglycemia?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Type 2, Susceptiblity to</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT080</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_type_2_susceptiblity_to?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Disease</Disease_Name>
      <Disease_Detail>Ovarian Disease</Disease_Detail>
      <Disease_DB>OVR049</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_disease?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Brain Cancer</Disease_Name>
      <Disease_Detail>Brain Cancer</Disease_Detail>
      <Disease_DB>BRN028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/brain_cancer?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypertension, Insulin Resistance-Related</Disease_Name>
      <Disease_Detail>Hypertension</Disease_Detail>
      <Disease_DB>HYP446</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypertension_insulin_resistance_related?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Metabolic Syndrome X</Disease_Name>
      <Disease_Detail>Metabolic Syndrome X</Disease_Detail>
      <Disease_DB>MTB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/metabolic_syndrome_x?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Noninsulin-Dependent, Late Onset</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_noninsulin_dependent_late_onset?search=INSR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Fiber-Type Disproportion</Disease_Name>
      <Disease_Detail>Congenital Fiber-Type Disproportion</Disease_Detail>
      <Disease_DB>CNG046</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_fiber_type_disproportion?search=INSR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Insulin receptor (IR) ectodomain in complex with fab's</PDB_Title>
      <PDB_ID>2DTG</PDB_ID>
      <Resolution>3.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2DTG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the insulin receptor ectodomain reveals a folded-over conformation</PubMed_Title>
      <Author>McKern NM</Author>
      <Journal>Nature. 2006 Sep 14;443(7108):218-21</Journal>
      <PubMed_ID>16957736</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Insulin receptor kinase complexed with an inhibitor</PDB_Title>
      <PDB_ID>3EKK</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3EKK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-fluoro-6-{[2-({2-methoxy-4-[4-(1-methylethyl)piperazin- 1-yl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin- 4-yl]amino}benzamide</Ligand_Name>
      <PubMed_Title>Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase</PubMed_Title>
      <Author>Chamberlain SD</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Jan 15;19(2):469-73</Journal>
      <PubMed_ID>19056263</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinase domain of insulin receptor complexed with a pyrrolo pyridine inhibitor</PDB_Title>
      <PDB_ID>3ETA</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3ETA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-(3-{5-[4-(aminomethyl)phenyl]-1H-pyrrolo[2,3- b]pyridin-3-yl}phenyl)-3-(2-phenoxyphenyl)urea</Ligand_Name>
      <PubMed_Title>Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase</PubMed_Title>
      <Author>Patnaik S</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Jun 1;19(11):3136-40</Journal>
      <PubMed_ID>19394223</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE</PDB_Title>
      <PDB_ID>1I44</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1I44</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER</Ligand_Name>
      <PubMed_Title>Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism</PubMed_Title>
      <Author>Till JH</Author>
      <Journal>J Biol Chem. 2001 Mar 30;276(13):10049-55</Journal>
      <PubMed_ID>11124964</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG</PDB_Title>
      <PDB_ID>1IR3</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1IR3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER</Ligand_Name>
      <PubMed_Title>Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog</PubMed_Title>
      <Author>Hubbard HR</Author>
      <Journal>EMBO J. 1997 September 15; 16(18): 5572-5581</Journal>
      <PubMed_ID>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1170189</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a complex between PTP1B and the insulin receptor tyrosine kinase</PDB_Title>
      <PDB_ID>2B4S</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2B4S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase</PubMed_Title>
      <Author>Li S</Author>
      <Journal>Structure. 2005 Nov;13(11):1643-51</Journal>
      <PubMed_ID>16271887</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB phosphopeptide</PDB_Title>
      <PDB_ID>3BU6</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3BU6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>O-PHOSPHOTYROSINE</Ligand_Name>
      <PubMed_Title>Structural and biochemical characterization of the KRLB region in insulin receptor substrate-4</PubMed_Title>
      <Author>Wu J</Author>
      <Journal>Nat Struct Mol Biol. 2008 Mar;15(3):251-10</Journal>
      <PubMed_ID>18278057</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the Grb14 BPS region in complex with the insulin receptor tyrosine kinase</PDB_Title>
      <PDB_ID>2AUH</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2AUH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14</PubMed_Title>
      <Author>Depetris RS</Author>
      <Journal>Mol Cell. 2005 Oct 28;20(2):325-33</Journal>
      <PubMed_ID>16246733</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Insulin receptor (domains 1-3)</PDB_Title>
      <PDB_ID>2HR7</PDB_ID>
      <Resolution>2.32</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2HR7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity</PubMed_Title>
      <Author>Lou M</Author>
      <Journal>Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12429-34</Journal>
      <PubMed_ID>16894147</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR</PDB_Title>
      <PDB_ID>1GAG</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1GAG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>THIOPHOSPHORIC ACID O-((ADENOSYL-PHOSPHO)PHOSPHO)- S-ACETAMIDYL-DIESTER</Ligand_Name>
      <PubMed_Title>Mechanism-based design of a protein kinase inhibitor</PubMed_Title>
      <Author>Parang K</Author>
      <Journal>Nat Struct Biol. 2001 Jan;8(1):37-41</Journal>
      <PubMed_ID>11135668</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Insulin receptor kinase complexed with an inhibitor</PDB_Title>
      <PDB_ID>3EKN</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3EKN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-fluoro-6-{[2-({2-methoxy-4-[4-(1-methylethyl)piperazin- 1-yl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin- 4-yl]amino}benzamide</Ligand_Name>
      <PubMed_Title>Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity</PubMed_Title>
      <Author>Chamberlain SD</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Jan 15;19(2):360-4</Journal>
      <PubMed_ID>19071018</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB peptide</PDB_Title>
      <PDB_ID>3BU3</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3BU3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>O-PHOSPHOTYROSINE</Ligand_Name>
      <PubMed_Title>Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2</PubMed_Title>
      <Author>Wu J</Author>
      <Journal>Nat Struct Mol Biol. 2008 Mar;15(3):251-8</Journal>
      <PubMed_ID>18278056</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor</PDB_Title>
      <PDB_ID>1RQQ</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1RQQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor</PubMed_Title>
      <Author>HU J</Author>
      <Journal>Mol Cell. 2003 Dec;12(6):1379-89</Journal>
      <PubMed_ID>14690593</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR</PDB_Title>
      <PDB_ID>1IRK</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1IRK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the tyrosine kinase domain of the human insulin receptor</PubMed_Title>
      <Author>Hubbard HR</Author>
      <Journal>Nature. 1994 Dec 22-29;372(6508):746-54.</Journal>
      <PubMed_ID>7997262</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a catalytic-loop mutant of the insulin receptor tyrosine kinase</PDB_Title>
      <PDB_ID>1P14</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1P14</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor</PubMed_Title>
      <Author>Li S</Author>
      <Journal>J Biol Chem. 2003 Jul 11;278(28):26007-14</Journal>
      <PubMed_ID>12707268</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB peptide and ATP</PDB_Title>
      <PDB_ID>3BU5</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=3BU5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ADENOSINE-5'-TRIPHOSPHATE</Ligand_Name>
      <PubMed_Title>Structural and biochemical characterization of the KRLB region in insulin receptor substrate-3</PubMed_Title>
      <Author>Wu J</Author>
      <Journal>Nat Struct Mol Biol. 2008 Mar;15(3):251-9</Journal>
      <PubMed_ID>18278056</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Phosphorylated insulin receptor tyrosine kinase in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin-2-yl]amino}phenyl)acetic acid</PDB_Title>
      <PDB_ID>2Z8C</PDB_ID>
      <Resolution>3.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=2Z8C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN- 2-YL}AMINO)PHENYL]ACETIC ACID</Ligand_Name>
      <PubMed_Title>Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors</PubMed_Title>
      <Author>Katayama N</Author>
      <Journal>Proteins. 2008 Dec;73(4):795-801</Journal>
      <PubMed_ID>18767165</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04960</Pathway_ID>
      <Pathway_Title>Aldosterone-regulated sodium reabsorption</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Excretory system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04930</Pathway_ID>
      <Pathway_Title>Type II diabetes mellitus</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04913</Pathway_ID>
      <Pathway_Title>Ovarian steroidogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04913</Pathway_ID>
      <Pathway_Title>Ovarian steroidogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04910</Pathway_ID>
      <Pathway_Title>Insulin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04152</Pathway_ID>
      <Pathway_Title>AMPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04022</Pathway_ID>
      <Pathway_Title>cGMP-PKG signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04068</Pathway_ID>
      <Pathway_Title>FoxO signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04520</Pathway_ID>
      <Pathway_Title>Adherens junction</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.daa.b.b.fg.html</SCOP_URL>
    <CATH_Class>Mixed alpha-beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1gag</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Kiselyov W, et al. Mol Syst Biol.2009,5:243.</Site_Reference>
      <Site_Type>Peptides-induced</Site_Type>
      <PubMed_ID>19225456</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>